Detection of human IgM or IgG antibodies against SARS-CoV-2 in serum and EDTA plasma
SARS-CoV-2 is a virus identified in the Chinese province of Wuhan at the turn of 2019/2020. It causes an acute infection of the respiratory tract designated as COVID-19 (Coronavirus disease 2019).
The main route for virus transmission is droplet infection. So far, the virus could be detected in nasal and pharyngeal secrets as well as e.g. in sputum, tear fluid, and feces (direct virus detection with PCR). The median incubation period is 5-6 days (1-14 days). Already during the incubation period, the transmission of the virus, even before symptom onset, is possible. Fever, cough and muscle aches are the most common symptoms, whereas fatigue, loss of smell and taste as well as diarrhoea might occur. Sever cases might rapidly progress to acute respiratory distress syndrome (ARDS) and might be complicated by coagulation disorders. These cases require an intensive medical care.
SARS-CoV-2 occurs as a high infective virus, which may also lead to asymptomatic infections. Therefore, as part of the pandemic control it is not sufficient to identify and isolate only patients with clinically noticeable symptoms. For that reason and as part of epidemiological studies it might be rather useful not to test only for the virus directly but also to test for IgM or IgG antibodies against SARS-CoV-2 in suspected COVID-19 cases.
Antibodies are produced as reaction to the virus antigen and can be used as serological diagnostic parameter after an infection with SARS-CoV-2. While IgM antibodies are formed during an early course of infection, the detection of IgG antibodies indicates a longer-lasting or previous infection.
Our ELISAs are specific for the detection of human IgM or IgG antibodies against the SARS-CoV-2 spike protein. Based on an internal cut-off control an unambiguous result interpretation is possible. Additionally, the tests are provided with a negative and a positive control. Human serum or plasma samples (10 µl) have to be diluted 1:101 in sample dilution buffer. To run the assay in duplicates 2 x 100 µl of this dilution can be used in the ELISAs.
IDK® anti-SARS-CoV-2 IgG ELISA (K 5000)
IDK® anti-SARS-CoV-2 IgM ELISA (K 5001)
Go to product information